Penumbra Inc
NYSE:PEN

Watchlist Manager
Penumbra Inc Logo
Penumbra Inc
NYSE:PEN
Watchlist
Price: 357.65 USD -0.38%
Market Cap: $14B

Operating Margin

13%
Current
Improving
by 6%
vs 3-y average of 6.9%

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
13%
=
Operating Income
$172.8m
/
Revenue
$1.3B

Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.

Operating Margin
13%
=
Operating Income
$172.8m
/
Revenue
$1.3B

Peer Comparison

Country Company Market Cap Operating
Margin
US
Penumbra Inc
NYSE:PEN
14.1B USD
Loading...
US
Intuitive Surgical Inc
NASDAQ:ISRG
185.8B USD
Loading...
US
Abbott Laboratories
NYSE:ABT
184.4B USD
Loading...
US
Boston Scientific Corp
NYSE:BSX
137.3B USD
Loading...
US
Stryker Corp
NYSE:SYK
136.8B USD
Loading...
IE
Medtronic PLC
NYSE:MDT
129.8B USD
Loading...
US
Becton Dickinson and Co
NYSE:BDX
57.6B USD
Loading...
DE
Siemens Healthineers AG
XETRA:SHL
47.7B EUR
Loading...
US
IDEXX Laboratories Inc
NASDAQ:IDXX
55B USD
Loading...
US
Edwards Lifesciences Corp
NYSE:EW
47.5B USD
Loading...
US
Resmed Inc
NYSE:RMD
37.6B USD
Loading...

Market Distribution

In line with most companies in the United States of America
Percentile
66th
Based on 14 112 companies
66th percentile
13%
Low
-4 087 900% — -5.1%
Typical Range
-5.1% — 14.8%
High
14.8% — 1 032 600%
Distribution Statistics
the United States of America
Min -4 087 900%
30th Percentile -5.1%
Median 6%
70th Percentile 14.8%
Max 1 032 600%

Penumbra Inc
Glance View

In the bustling landscape of medical technology, Penumbra Inc., founded in 2004, has etched a significant footprint by concentrating on an often-underexplored niche: therapies for neurovascular and peripheral vascular diseases. The company began its journey focusing primarily on devices to treat conditions like strokes, introducing its first product, the Penumbra System, swiftly after its inception. By innovating in thrombectomy techniques, Penumbra has provided interventionalists with the tools to effectively remove clots in the brain and restore blood flow, a crucial factor in minimizing stroke damage. The firm's pioneering spirit and commitment to addressing the unmet needs in the medical field have propelled its growth, driven by an unyielding focus on enhancing clinical outcomes for patients facing critical vascular conditions. Penumbra's success hinges not just on innovative product development but also on a comprehensive business model that centers around high-impact therapeutic solutions. It generates revenue through the sale of these specialized medical devices, primarily to hospitals and healthcare facilities across the globe. By leveraging cutting-edge technology and collaboration with healthcare professionals, Penumbra continually broadens its product portfolio, including devices for peripheral vascular interventions and embolization therapies. This focus on expanding clinical applications and adapting to emerging medical challenges ensures that Penumbra stays at the forefront of innovation, enabling it to capture a growing share of the global healthcare market. Through its focused approach, Penumbra not only makes strides in advancing medical treatments but also fortifies its position as a formidable player in the field of therapeutic medical devices.

PEN Intrinsic Value
139.47 USD
Overvaluation 61%
Intrinsic Value
Price
What is Operating Margin?
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
How is Operating Margin calculated?

Operating Margin is calculated by dividing the Operating Income by the Revenue.

Operating Margin
13%
=
Operating Income
$172.8m
/
Revenue
$1.3B
What is Penumbra Inc's current Operating Margin?

The current Operating Margin for Penumbra Inc is 13%, which is above its 3-year median of 6.9%.

How has Operating Margin changed over time?

Over the last 3 years, Penumbra Inc’s Operating Margin has increased from -4.7% to 13%. During this period, it reached a low of -4.7% on Sep 30, 2022 and a high of 13% on Sep 30, 2025.

Back to Top